|
|
|
| Analysis of clinicopathology and outcome of childhood Henoch-Schonlein purpura nephritis with endocapillary proliferation |
| FU Gui, HE Xiaoqing, HU Yunxia, YU Lingfang, YANG Qing, ZHUANG Jieqiu. |
Department of Paediatric Nephrology, the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Whenzhou, 325027
|
|
| Cite this article: |
|
FU Gui,HE Xiaoqing,HU Yunxia, et al. Analysis of clinicopathology and outcome of childhood Henoch-Schonlein purpura nephritis with endocapillary proliferation[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(5): 330-334.
|
|
|
Abstract Objective: To investigate the clinicopathogical characteristics and outcome of Henoch-Schonlein purpura nephritis with endocapillary proliferation (EP-HSPN) in children. Methods: Retrospectively analyzed the clinicopathology and follow-up data of children whom were biopsy-proven EP-HSPN in our hospital from January 2005 to June 2013, and the contemporary non-EP-HSPN children were chosen as control group. Further comparisons among the EP-HSPN cases were performed. Results: ①In contrast to the 44 cases of non-EP-HSPN group, the 46 cases of EP-HSPN group showed younger, a shorter course of disease, joint and gastrointestinal tract more presented involvement, nephrotic level of proteinuria, hypoalbuminemia, nephrotic syndrome type, grade III lesion, a higher rate of crescent and capillary loops necrosis, but slighter damage of renal tubular interstitial. ②In 46 cases in children with EP-HSPN, compared with the 33 cases of non-DEP-HSPN, 13 cases of DEP-HSPN had heavy proteinuria, higher BUN, more showed nephrotic level of proteinuria, hypoalbuminemia and nephrotic syndrome type, less presented hematuria and proteinuria type. ③For EP-HSPN children, more given steroid in combination with cyclophospamide treatment (50%), whereas for non-EP-HSPN, more given symptomatic treatment (47.7%). The follow-up results of two groups showed no statistically significant differences in outcome. Conclusion: EP-HSPN shows severity of clinical manifestations and glomerular pathological changes. Immunosuppressant treatment in the early stage of disease is effective for a short term outcome.
|
|
Received: 25 November 2015
|
| |
|
|
|
|
|
|
